Tests Xeomin injections in the arm and walking after stroke
Tests Xeomin injected into the arm to see changes in walking in adults after stroke.
Plain-language title generated from the registry record
Registry title: Xeomin® and Gait Related Mobility After Stroke
Key facts
- Where
- Charlotte, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Source: NCT04908423, who can take part
Where in United States
- Carolinas RehabilitationCharlotte, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT04908423
- Record updated
- 26 October 2026
- Original description
The aim of the present pilot study is to evaluate the association between change in gait related mobility in ambulatory male and female adult hemiparetic patients before and 4-6-weeks after Xeomin® injection into the upper limb, using two standardized tests of physical function in outpatient rehabilitation that are widely used; the 10-meter walk test and the timed 'up and go' test (TUG).Read full original descriptionShow less
Upper Extremity Injection of Xeomin® and Changes in Gait Related Mobility in Adults After Stroke
The aim of the present pilot study is to evaluate the association between change in gait related mobility in ambulatory male and female adult hemiparetic patients before and 4-6-weeks after Xeomin® injection into the upper limb, using two standardized tests of physical function in outpatient rehabilitation that are widely used; the 10-meter walk test and the timed 'up and go' test (TUG).
Inclusion: Diagnosis of hemiparesis and spasticity secondary to stroke with upper and lower limb spasticity and unilateral motor and/or sensory deficit; No prior surgery to the lower limb; Able to walk at least 10 meters without physical assistance from another person and without an assistive device; Toe- ground clearance during swing phase without assistive device or orthoses; No treatment with botulinum toxin within the past 4 months.
Exclusion: Weight bearing restrictions due to concurrent orthopedic injuries that would make ambulating with or without an assistive device unsafe; Participants with uncorrected hearing impairment; Other confounding neurological diagnoses or active acute illness (cancer, Parkinson's disease, multiple sclerosis); Passive range of motion at either the ankle, knee, or elbow joint less than 30 degrees; Speech language expression deficit (e.g., aphasia); Absence of proprioception upon neurologic examination; Presence of fixed contractures in the upper or lower extremities not correctable to neutral.